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INTRODUCTION
The filovirus family includes Marburg virus and five ebolaviruses (Ebola, Sudan, Reston, Bundibugyo, and Taï Forest viruses), most of which cause highly lethal hemorrhagic fever and multiple outbreaks among humans. Among the filoviruses, Marburg virus was the first to be identified when it sickened laboratory workers in Europe in 1967 (Malherbe and Strickland-Cholmley, 1968; Siegert et al., 1968) . Marburg virus has since re-emerged multiple times, with modern strains conferring greater lethality ($90%) (Geisbert et al., 2007; Towner et al., 2006) . Sudan virus has caused at least six outbreaks between 1976 and 2013 (Albariñ o et al., 2013; Bowen et al., 1977; Sanchez and Rollin, 2005; Shoemaker et al., 2012) , Bundibugyo virus emerged in 2007 (Towner et al., 2008; Wamala et al., 2010) and again in 2012 (Albariñ o et al., 2013) , and Reston virus was found to infect ranches of swine being raised for human consumption in Asia in 2009 and 2011 (Barrette et al., 2009; Pan et al., 2014; Sayama et al., 2012) . Ebola virus is typically found in Central Africa, but reemerged in Western Africa in 2014 to cause an outbreak unprecedented in magnitude and geographic spread (WHO Ebola Response Team, 2014) . During this outbreak, an experimental Ebola virus-specific monoclonal antibody (mAb) cocktail ) was used compassionately in several patients. No such treatment yet exists that could be used against Marburg virus or the other four ebolaviruses.
Filoviruses express a single protein on their envelope surface, a glycoprotein termed GP, which is responsible for attachment to, and entry of, host cells (Sanchez et al., 1996) . GP forms a trimer on the viral surface. In the trimer, each monomer is comprised of GP1 and GP2 subunits that are anchored together by a GP1-GP2 disulfide bond (Volchkov et al., 1998) . GP1 contains a receptor-binding core topped by a glycan cap and a heavily glycosylated mucin-like domain (Lee et al., 2008) , while GP2 contains two heptad repeats and a transmembrane domain. Filoviruses initially enter cells via macropinocytosis (Aleksandrowicz et al., 2011; Nanbo et al., 2010; Saeed et al., 2010; Mulherkar et al., 2011) . Once in the endosome, the viral surface GP is cleaved by host cathepsins. Cleavage removes the mucin-like domains and glycan cap (Chandran et al., 2005; Schornberg et al., 2006; Hood et al., 2010; Marzi et al., 2012a; Brecher et al., 2012) and renders GP competent to bind the Niemann Pick C1 (NPC1) receptor (Carette et al., 2011; Cô té et al., 2011) . Interestingly, Ebola virus entry requires cleavage by cathepsin B (Chandran et al., 2005; Martinez et al., 2010; Schornberg et al., 2006) , while Marburg virus entry is independent of cathepsin B (Gnirss et al., 2012; Misasi et al., 2012) . The reasons underlying these differences are unknown. After enzymatic cleavage and receptor binding, the GP2 subunit unwinds from its GP1 clamp and rearranges irreversibly into a six-helix bundle (Malashkevich et al., 1999; Weissenhorn et al., 1998a; Weissenhorn et al., 1998b) to drive fusion of virus and host membranes.
Antibody therapies recently have demonstrated effective post-exposure protection against filoviruses in animal models (Dye et al., 2012; Marzi et al., 2012b; Olinger et al., 2012; Pettitt et al., 2013; Qiu et al., 2012; Qiu et al., 2014) . MAbs can be produced on large scale and offer more reproducible effects than polyclonal sera from survivors. However, most mAbs available only recognize Ebola virus. Very few are yet described against Marburg virus, and no antibodies are yet described that crossreact among the filoviruses. Indeed, Marburg and Ebola GP are 72% different in protein sequence, and the filoviruses are thought to be antigenically distinct. Further, there is no structure available for the unique Marburg virus GP, by which we may interpret differences in requirements for viral entry, or develop immunotherapeutics or inhibitors of entry.
Here, we report the crystal structure of the trimeric, receptorcompetent form of Marburg virus GP in complex with a neutralizing antibody, termed MR78, that was identified in a recent human survivor of Marburg virus infection (Flyak et al., 2015) . Atypically, MR78 cross-reacts to cleaved Ebola virus GP. An additional structure of MR78 in complex with Ebola virus GP illustrates the basis of the cross-reactivity: the antibody binds a hydrophobic ''trough'' at the top of GP1, the sequence and structure of which are conserved across the filoviruses. We propose that this trough is the binding site of the critical domain C of the NPC1 receptor. Indeed, MR78 blocks binding of domain C to Marburg GP. Further, the extended third complementaritydetermining region of the heavy chain (CDR H3) of MR78 mimics the glycan cap that shields this site on Ebola virus prior to entry and may mimic the receptor itself. These crystal structures plus additional biophysical analysis of complete, mucin-containing Ebola and Marburg GP ectodomains reveal that the receptorbinding site is masked on the surface of Ebola virus but more exposed on the surface of Marburg virus. These findings may explain why a cross-reactive antibody such as MR78 has not been identified in studies of Ebola virus.
RESULTS

Structure Determination
Trimeric GP ectodomains for Marburg virus (MARV; strain Ravn) or Ebola virus (EBOV, also known as Ebola Zaire; strain Mayinga) were expressed in Drosophila S2 cells, with or without their mucin-like domains (GP and GPDmuc, respectively). MARV and EBOV GPDmuc were further proteolyzed by trypsin or thermolysin, respectively, to produce cleaved GP (GPcl) resembling the version of GP competent for receptor binding in the endosome ( Figure S1A ). Three hundred versions of MARV GP were engineered and complexed with 22 different mAbs in order to find a crystallizable combination. Hundreds of crystals of the final MARV GPcl-MR78 combination were grown and screened for X-ray diffraction: just one crystal yielded suitable diffraction.
Diffraction to 3.6 Å resolution was obtained from a single crystal of the MARV GPcl-Fab MR78 complex. The structure was determined by molecular replacement using EBOV GP and Fab KZ52 (Lee et al., 2008) as search models and was refined to R work of 24.7 % and R free of 27.9 % (Table S1 ). Four GP-Fab complexes are contained in the asymmetric unit: one complete trimer and one other monomer, which forms its biologically relevant trimer around a crystallographic 3-fold axis.
Differences in GP Structure between EBOV and MARV Although the overall organization is similar between Marburg and Ebola GPs (1.8 Å rmsd among 212 Ca atoms) ( Figures 1A and  1B) , several structural differences exist that may explain their differing requirements for cellular entry. The first difference is that the intra-GP1 disulfide bond formed by C121 and C147 in ebolavirus GP structures (Ebola [Lee et al., 2008] and Sudan [Bale et al., 2012; Dias et al., 2011] ) does not exist in MARV. In MARV, the two cysteines are replaced instead with L105 and H131 ( Figure 1C and Figure S1B ). As a result, the equivalent polypeptides, which form the crest of the receptor-binding subunit, differ in structure and flexibility. In the ebolaviruses, the polypeptide bearing C147 (residues 145 to 150) turns inward, toward the trimer center to disulfide bond to C121. In MARV, the equivalent polypeptide (residues 129 to 134) turns outward into solvent, away from the trimer center.
A second difference between MARV and the ebolaviruses lies at the base of the cathepsin cleavage loop. In MARV, these residues (172-180) form a clear alpha helix (a2), which packs against the outside of the GP2 fusion loop, interacting with both the Nand C-terminal strands of the fusion loop ( Figure 1D ). In ebolaviruses, the equivalent residues predict to form a loop rather than a helix and are disordered (Bale et al., 2012; Dias et al., 2011; Lee et al., 2008) . In MARV GP, the peptide connecting this a2 helix to b14 in the glycan cap would necessarily and immediately cover the both N-and C-terminal arms of the GP2 fusion loop, and if uncleaved, would hinder the conformational changes of fusion. Structural differences in a2 of MARV may prevent effective processing by cathepsin B.
The third difference in the MARV GP structure lies at the N terminus, in the base of the b sheet that forms the GP1 spool, about which the metastable GP2 subunit is wound. In EBOV, the base of the spool connects to the anchoring GP1-GP2 disulfide bond by a short stretch of polypeptide that intimately interacts with GP2. This short connecting polypeptide contains an N-linked glycan at Asn40, and also contains residue Asp47, which renders EBOV dependent on cathepsin B for entry (Misasi et al., 2012) . In EBOV entry, cathepsin B removes an additional and critical 1 kDa of mass from GP beyond that removed by cathepsin L, but the site and consequences of that extra cleavage event are not yet known. We propose that if cathepsin B cleaves this connecting loop, EBOV GP2 would be freed from the constraints of the disulfide bond and better able to undergo the conformational rearrangements of fusion. Our crystal structure reveals that MARV, which is cathepsin B-independent, is structured differently from EBOV at the same site. In MARV, the base of the GP1 spool is more mobile and is shifted toward the center of the trimer, inside of the fusion loop. Further, unlike in ebolaviruses (Dias et al., 2011; Bale et al., 2012) , the polypeptide connection to the MARV GP1-GP2 disulfide could not be visualized and the N-linked glycan is absent. The nearest glycan is instead attached to residue 171 on the MARV GP1 b sheet itself ( Figure 1E ). These differences in sequence, glycosylation, mobility, and conformation likely allow MARV to be cleaved by other enzymes and render MARV cathepsin B-independent.
Overall Organization of the MARV or EBOV GPcl Bound to Fab MR78 The crystal structure of MARV GPcl in complex with the Fab fragment of MR78 indicates that MR78 binds the membrane-distal head of GP1 ( Figure 2A ). We determined an additional, low-resolution structure of EBOV GPcl bound to both MR78 and KZ52. The ternary EBOV complex, determined by molecular replacement, demonstrates that the MR78 antibody recognizes a similar site on both MARV and EBOV (Figures 2B, S2, and Table S1 ). MR78 binds into a highly conserved hydrophobic trough revealed at the top of the EBOV GP1 core, after removal of the glycan cap by proteolytic cleavage in the endosome. Although MARV and EBOV diverge significantly in sequence overall, residues contained in this site, the MR78 epitope, are 85% similar between the viruses (Figures 3A and S1B).
Likely Receptor-Binding Site
The location and structural conservation of this site suggest that it could be the binding site of the NPC1 receptor, used by all known filoviruses (Carette et al., 2011; Cô té et al., 2011; Miller et al., 2012; Ng et al., 2014) . Indeed, in ELISA, MR78 inhibits binding of NPC1 domain C to MARV GP ( Figure S3A ). This site, at the apex of cleaved GP1, resembles an ocean wave morphology, with a lower trough beneath a rising crest. The trough is hydrophobic and is formed by a1, b4 and the loop that connects them (residues 63-74 in MARV). It is 22 Å wide and 8 Å deep at F72. The crest is hydrophilic, includes charged residues previously identified as essential for virus entry (Dube et al., 2009; Manicassamy et al., 2005; Manicassamy et al., 2007) , and is formed by strands b7, b9 and their connecting loops (residues 92-106 and 120-134 in MARV). The 120-134 loop contains H131, which replaces the cysteine and the intra-GP1 disulfide bond of EBOV ( Figure 3B ).
Here, we show by ELISA that a Q128S and N129S double mutant in MARV GP abrogates binding to NPC1 domain C (Figure S4A ). Q128 and N129 are at the tip of the crest and could make direct hydrophilic interaction with NPC1. The trough itself is formed by hydrophobic side chains, such as F72 (equivalent to F88 in EBOV). Also forming the trough are the main chains of hydrophilic residues; these polar side chains reach away from the trough into the trimer to make key stabilizing contacts to GP2. Two examples are R73 and K79, previously shown to be essential for MARV infectivity (Manicassamy et al., 2007) . In the crystal structure, R73 makes multiple hydrogen bonds to the fusion loop (A) Crystal structure of MARV GPcl (GP1, purple and GP2, dark gray) superimposed with the equivalent structure of EBOV (PDB ID, 3CSY; GP1, blue; and GP2, light gray). The glycan cap of EBOV GP is deleted for clarity. The yellow box outlines the MR78 epitope and putative receptor-binding site. The black box outlines the interaction site of the MARV-specific helix a2 of GP1 (purple) with the fusion loop of GP2 (dark gray). The visible N-linked sugars on MARV and EBOV GPcl crystal structures are shown as dot models. MARV GPcl bears glycans at positions N94 and N171, which are not glycosylated in EBOV. See also Figure S1 . (B) Top view of GP. (C) MARV GP lacks the intra-GP1 disulfide bond of EBOV. C147 of EBOV (blue) is replaced by H131 in MARV (purple), and the corresponding polypeptide traces outward from the trimer center. The orange box outlines the glycan attachment sites at the base of each GP. (D) Residues 172-180 of MARV form an a helix (a2) that packs against both N-and C-terminal arms of the fusion loop. In ebolaviruses, the equivalent residues are predict to form a loop rather than a helix and are disordered in crystal structures. (E) At the base of GP, MARV bears a glycan attached to N171 while EBOV bears a glycan attached to N40 (drawn as an oval as it was not included in the EBOV crystal structure).
of the neighboring protomer in the trimer ( Figure S4B ) and likely plays a key role in maintaining the prefusion structure or transmitting a conformational change to the fusion loop after receptor binding. K79 interacts with the main chain of residues 574-577 of GP2 ( Figure S4C ), residues that connect the separated helical segments of the first heptad repeat. We propose that binding of NPC1 domain C involves contact with the hydrophilic crest and hydrophobic trough, and that binding in the trough may transmit conformational changes to GP2 via R73 and K79 (equivalent to R89 and K95 in EBOV). Although MR78 binds both MARV and EBOV GPcl, it only outcompetes NPC1 domain C for binding of MARV GPcl ( Figure S3B ). MR78 may have lower affinity for EBOV GPcl than MARV GPcl or domain C may bind the GPs slightly differently.
GP-MR78 Interactions
The interaction surface between the MR78 antibody and MARV GP buries 976 Å 2 of molecular surface and is primarily hydrophobic. Contact is mediated by both the heavy and light chains, but the primary region of interaction is the 17-residue CDR H3 (Figures 3C and S3CD) , which penetrates the hydrophobic trough in MARV GP1. In this interaction, F111.2 and Y112.2 of the CDR H3 interact with P63, S67, W70, F72, I95 and I125 of MARV GP (IMGT numbering, Figure 4A) . Notably, these interactions are similar to those made by the Ebola virus glycan cap, which occupies this site prior to enzymatic cleavage in the endosome. In Ebola virus, the equivalent interactions are made by F225 and Y232 of the EBOV glycan cap interacting with P80, T83, W86, F88, L111 and V141 on EBOV GP ( Figure 4B ). Similarity may even extend to the key domain C of the NPC1 receptor itself, as domain C contains similar Phenylalanine and Tyrosine residues that are essential for binding GP (Ndundo and Chandran, personal communication). Further, F72 in MARV, which is equivalent to F88 in EBOV, interacts with CDR H3 in the bottom of the trough. Both F72 of MARV and F88 of EBOV are critical for attachment and entry (Martinez et al., 2013; Mpanju et al., 2006) and may interact directly with essential hydrophobic residues of domain C. The binding mode of MR78 is reminiscent of anti-influenza virus human mAbs in which long CDR H3s similarly reach into the conserved receptor-binding site (Barbey-Martin et al., 2002; Bizebard et al., 1995; Hong et al., 2013; Lee et al., 2014; Schmidt et al., 2013; Whittle et al., 2011; Xu et al., 2013) . In many cases those influenza mAbs also use Phe or Tyr aromatic residues to interact with an aromatic residue in the viral receptor binding domain, suggesting that the favorable energetics and intermolecular interactions of common aromatic molecules may constitute a canonical mode of binding of antiviral antibodies to recessed receptor-binding sites.
Although the MR78 epitope is largely conserved in sequence and structure between MARV and EBOV, it differs in its exposure at different stages of virus entry. MR78 binds MARV GP equally well whether MARV GP is in its uncleaved, viral-surface form or its cleaved, endosomal form. In contrast, MR78 does not bind uncleaved EBOV GP. It only binds the endosomal, cleaved form from which the glycan cap has been removed. Together, these results suggest that in EBOV, the glycan cap effectively blocks the MR78 epitope and putative receptor-binding site on the (uncleaved) viral surface, but that in MARV, the epitope and at least part of the receptor-binding site is fully exposed on the viral surface. Better exposure of this site may explain why antibodies against the putative receptor-binding site were elicited by MARV infection (see companion paper by Flyak et al., 2015) , but seem to be more rarely elicited and have not yet been described against EBOV.
Differences in Mucin-Like Domains between MARV and EBOV, and Possible Effect on Antibody Reactivity
In addition to a glycan cap, the GP spike on the viral surface includes three heavily glycosylated mucin-like domains that are $75 kDa each in mass and are predicted to have little secondary structure. All mucin-containing GPs thus far have been refractory to crystallization. In order to visualize the native glycoprotein ectodomain and position of the mucin-like domain relative to the receptor-binding core, we turned to Small-Angle X-ray Scattering (SAXS) in solution. SAXS data collected for mucin-containing EBOV or MARV GP trimers indicate that the mucin-like domains of both viruses are large and extend outward from the GP core. The radius of gyration, R G , for mucin-deleted and mucin-containing MARV GPs are 50 and 72 Å , respectively, and maximum dimension, D max , for mucin-deleted and mucin-containing GPs are 160 and 250Å , respectively, indicating that the mucin-like domain of MARV widens the molecule up to 90 Å ( Figures 5A  and S5 ). The mucin-like domains of MARV are a bit larger than those of EBOV (67 Å R G and 225 Å D max for mucin-containing EBOV GP), consistent with their greater volume determined by SAXS ( Figure S5C ) and mass noted by SDS-PAGE ( Figure S5D ). The mucin-like domains of EBOV appear to project more upward (consistent with EM tomography [Tran et al., 2014] ), while those of MARV appear to project less upward, more equatorially, and to cover the sides of the GP trimer ( Figures 5A and 5B) . Although the mucin-like domains are likely flexible (see PorodDebey coefficient P in Figure S5C ), an equatorial, rather than upward projection is consistent with attachment points of the mucin-like domain to both GP1 and GP2 in MARV. In EBOV, a different position of the furin cleavage site results in all of mucin-like domain being attached to GP1. The MARV GP2 portion of the mucin-like domain, residues 436-509, is attached to residue 510 on the side of the MARV GP trimer, but is flexible and disordered.
A differing position of the mucin-like domains between MARV and EBOV would leave different surfaces exposed for immune recognition. The equatorial projection of the MARV mucin-like domain, for example, would leave the expected receptor-binding site at the top more accessible on MARV than EBOV, and further supports the notion that antibodies against the expected receptor-binding site would be more likely to be elicited using marburgvirus antigens than ebolavirus antigens. The accompanying paper (Flyak et al., 2015) and other immunization studies (Qiu et al., 2011; Wilson et al., 2000) support this notion.
In contrast, on EBOV, the upward projection of the mucin-like domains and the absence of mucin attached to EBOV GP2 would leave the EBOV base more exposed for antibody surveillance, compared to that of MARV. Indeed, in the accompanying paper by Flyak et al., none of the 18 neutralizing antibodies raised against MARV appear to bind the base of the MARV GP, while multiple neutralizing antibodies elicited by ebolaviruses are known to bind, or thought to bind, to the base of ebolavirus GP (Dias et al., 2011; Lee et al., 2008; Qiu et al., 2012; Murin et al., 2014) (Figure 5C ).
DISCUSSION
In summary, the crystal structures and accompanying experiments indicate that MR78 binds a conserved site on the apex of GP1 that is available on the surface of MARV GP, but masked on EBOV GP prior to enzymatic cleavage. The epitope of MR78 likely overlaps with the receptor-binding site, and hydrophobic contacts made by CDR H3 to the hydrophobic trough may mimic (A) Conservation of the MR78 epitope among filovirus GPs, mapped onto one monomer of MARV GPcl. Sequence alignment was performed in ebolavirus (Ebola, Sudan, Reston, Taı¨Forest, Bundibugyo) , marburgvirus (Musoke, Angola, Popp, Ci67, DRC1999, Ravn), and cuevavirus (Lloviu) genuses. Residues identical across the filoviruses are colored red; residues that possess strong similarity, magenta; weak similarity, pink; no similarity, gray. (B) The apex of cleaved MARV GP1, where Fab MR78 binds, forms a wave crest-and-trough morphology (magenta). The hydrophilic crest and the hydrophobic trough each contain residues previously shown to be critical for virus entry (Dube et al., 2009; Manicassamy et al., 2005; Manicassamy et al., 2007; Mpanju et al., 2006) . The diagonal black line indicates the base of the trough. See also Figure S4 . (C) Surface representation of the interface between one monomer of MARV GPcl (bottom) and Fab MR78 (top). CDR H1 is colored red; CDR H2, orange; CDR H3, purple; CDR L1, blue; CDR L2, green; CDR L3, forest green. The footprint on MARV GPcl is colored according to the CDR that mediates the contact. GP residues contacted by MR78 are indicated and colored according to the CDR that mediates the contact (CDR names in parentheses).
those of the as-yet-unvisualized NPC1 domain C. MR78 does not neutralize authentic EBOV, likely because its epitope is masked on the EBOV surface by the mucin-like domain and glycan cap on the virus surface. MR78 does, however, neutralize authentic MARV (Flyak et al., 2015) and could be a valuable monoclonal antibody therapeutic against this extremely lethal virus. Importantly, no mAb therapeutic yet exists against MARV, and few mAbs are yet known against MARV from which such a therapeutic could be developed. The crystal structure of MARV GP presented here, and the highly conserved MR78 epitope, provide strategies for immunotherapy and templates for development of potentially broad-spectrum inhibitors of filovirus entry.
EXPERIMENTAL PROCEDURES
Construction, Expression, and Purification of MARV/EBOV GP DNA encoding the MARV GPDmuc ectodomain (residues 1-636 with a mucin deletion of residues 257-425), point mutants of MARV GPDmuc and the EBOV GPDmuc ectodomain (residues 1-637 with a mucin deletion of residues 314-462) were amplified by PCR using codon-optimized and whole-gene synthesized MARV or EBOV GPs as templates. Four point mutations in MARV GPDmuc, F438L, W439A, F445G, and F447N, on GP2, located around the furin cleavage site were found to improve the efficiency of furin cleavage. GP constructs were cloned into a derivative of the expression vector pMT. This derivative vector contains the puromycin resistant gene and a C-terminal double-strep tag sequence. Expression plasmids were transfected using Effectin (QIAGEN) into 80% confluent Drosophila Schneider S2 cells. The cells were first cultured in complete Schneider's medium supplemented with 10% (v/v) FCS (LONZA), and were adapted to Insect Xpress medium by progressively modifying the Schneider/Insect Xpress medium ratio with 6.0 mg/ml puromycin. Large-scale expression of the MARV/EBOV GPDmuc was performed using stable S2 cell lines in 2 l Erlenmeyer flask at 27.0 C, induced with 0.5 mM CuSO 4 . Supernatants containing the expressed proteins were harvested 4 days after induction, and mixed with the Strept-Tactin affinity column binding buffer (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 15 mg/ml Avidin [pH8.0]). The proteins were purified via Strept-Tactin affinity, followed by Superdex 200GL 10/300 (GE Healthcare Life Sciences) size-exclusion chromatography (S200 SEC). 
Preparation and Crystallization of GPAntibody Complexes
To mimic endosomal protease cleavage and produce MARV GPcl, MARV GPDmuc was incubated with 0.01 mg trypsin at 37 C for 1 hr in 20 mM TBS [pH 8.0], 100 mM NaCl. The reaction was stopped using 0.5 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), and the protein was purified by S200 SEC. EBOV GPcl was produced by incubating EBOV GPDmuc with 0.02 mg thermolysin overnight at room temperature in 20 mM TBS [pH 7.5], 100 mM NaCl, 1 mM CaCl 2 , and purified by S200 SEC. Hybridoma cells expressing the human MR78 antibody were generated from peripheral blood mononuclear cells (PBMCs) from a donor, who contracted MARV infection in the Python Cave in Queen Elizabeth National Park, Uganda in 2008 (see Flyak et al., 2015) . MR78 was expressed in serum-free medium (Hybridoma-SFM, GIBCO), and culture supernatants were centrifuged, sterile-filtered, and purified over HiTrap Protein G columns (GE Healthcare Life Sciences). Fab fragments were generated by standard papain digestion, with released Fc and undigested IgG removed by Protein A chromatography, and remaining Fab fragments further purified by MonoQ ion-exchange chromatography. For crystallization, purified MARV GPcl was mixed with excess Fab MR78 for 2 days at 4 C. Complexes were separated from unbound Fab via S200 SEC. Crystals were grown by hanging-drop vapor diffusion at 20 C using 0.8 ml protein (13.0 mg ml À1 , in 20 mM Tris-HCl [pH 8.0], 100 mM NaCl) and 0.8 ml of mother liquor (100 mM NaCl, 50 mM MES [pH 6.5], 13 % PEG 4000, 0.5 % ethyl acetate). These crystals were cryoprotected with 25% glycerol plus mother liquor before flash cooling in liquid nitrogen. One crystal diffracted to a resolution of 3.6 Å . EBOV GPcl was complexed with Fabs KZ52 and MR78 and crystallized using hanging-drop vapor diffusion at 20 C with 1.0 ml of protein (6 mg/ml, 150 mM NaCl, 10 mM Tris [pH 7.5]) and 1.0 ml of mother liquor (100 mM NaAcetate [pH 4.6], 200 mM NH4SO4, 10% PEG 3350, 2% PEG 400). The crystals were then cryoprotected by washing in 100 mM NaAcetate [pH 4.6], 200 mM NH4SO4, 12% PEG 3350, 10% PEG 400, 10% ethylene glycol. Only diffraction to 8 Å was obtained, but this data permitted molecular replacement using Phaser (McCoy et al., 2007) and EBOV GP and KZ52 (Lee et al., 2008) as search models.
ACCESSION NUMBERS
Coordinates and structure factors have been deposited into the Protein Data Bank under the accession code 3X2D. 
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